345 related articles for article (PubMed ID: 8935395)
1. Tamoxifen in postmenopausal women a safety perspective.
Robinson E; Kimmick GG; Muss HB
Drugs Aging; 1996 May; 8(5):329-37. PubMed ID: 8935395
[TBL] [Abstract][Full Text] [Related]
2. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogen-receptor modulators in 2001.
O'Regan RM; Gradishar WJ
Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
[TBL] [Abstract][Full Text] [Related]
4. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Mäenpää JU; Ala-Fossi SL
Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
[TBL] [Abstract][Full Text] [Related]
5. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
[TBL] [Abstract][Full Text] [Related]
6. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
Jordan VC
Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
[TBL] [Abstract][Full Text] [Related]
7. Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women.
Timmerman D; Neven P; Deprest J; Konstantinović ML; Vergote I
Cancer; 2003 Jul; 98(2):431-2; author reply 432-3. PubMed ID: 12872366
[No Abstract] [Full Text] [Related]
8. The role of tamoxifen in the treatment and prevention of breast cancer.
Jordan VC
Curr Probl Cancer; 1992; 16(3):129-76. PubMed ID: 1582240
[TBL] [Abstract][Full Text] [Related]
9. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
11. [Surveillance of patients treated with tamoxifen].
Sananes S; Khairallah T; Touboul E; Salat-Baroux J; Uzan S
Presse Med; 1996 Mar; 25(10):499-502. PubMed ID: 8685111
[TBL] [Abstract][Full Text] [Related]
12. Endometrial lesions after tamoxifen therapy in breast cancer women.
Maugeri G; Nardo LG; Campione C; Nardo F
Breast J; 2001; 7(4):240-4. PubMed ID: 11678801
[TBL] [Abstract][Full Text] [Related]
13. Development of a new prevention maintenance therapy for postmenopausal women.
Jordan VC
Recent Results Cancer Res; 1999; 151():96-109. PubMed ID: 10337721
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of tamoxifen therapy.
Assikis VJ; Jordan VC
Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):21-3. PubMed ID: 9065923
[TBL] [Abstract][Full Text] [Related]
15. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.
Zidan J; Keidar Z; Basher W; Israel O
Med Oncol; 2004; 21(2):117-21. PubMed ID: 15299183
[TBL] [Abstract][Full Text] [Related]
16. MR appearance of endometrial carcinoma and mucinous cystadenoma in a postmenopausal patient treated with tamoxifen for breast cancer.
Joja I; Asakawa T; Ando Y; Shiraiwa M; Shibutani O; Akaki S; Kuroda M; Mizutani Y; Kudo T; Hiraki Y
Radiat Med; 1998; 16(4):315-9. PubMed ID: 9814431
[TBL] [Abstract][Full Text] [Related]
17. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
19. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen.
Schwartz LB; Snyder J; Horan C; Porges RF; Nachtigall LE; Goldstein SR
Ultrasound Obstet Gynecol; 1998 Jan; 11(1):48-53. PubMed ID: 9511196
[TBL] [Abstract][Full Text] [Related]
20. Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups.
Schlesinger C; Kamoi S; Ascher SM; Kendell M; Lage JM; Silverberg SG
Int J Gynecol Pathol; 1998 Oct; 17(4):302-11. PubMed ID: 9785130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
